secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2026-08-13T11:25:27+00:00
Accession:  0001104659-26-095460
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Q2 net loss $6.9M; cash $34M; Phase 3 iopofosine trial site activation started
--------------------------------------------------------------------------------

- Net loss $6.9M ($0.57/share) vs $5.4M ($3.39/share) in Q2 2025; R&D up to $4.6M from $2.4M.
- Cash $34.0M at June 30, 2026 vs $13.2M at Dec 31, 2025; funded into Q2 2027.
- Initiated site activation for confirmatory Phase 3 iopofosine I 131 in WM; NDA planned mid-2027 under accelerated approval.
- Dosed first patients in Phase 1b CLR 125 for triple-negative breast cancer.
- May 2026 financing: ~$35M upfront, up to $105M milestone-based securities to fund Phase 3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/0001104659-26-095460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/tm2623056d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-095460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer